TY - GEN
T1 - Safety evaluation of the food enzyme β-amylase from genetically modified Bacillus licheniformis strain NZYM-JA
AU - EFSA Panel on Food Contact Materials Enzymes, Flavourings and Processing Aids (CEF)
AU - Silano, Vittorio
AU - Bolognesi, Claudia
AU - Castle, Laurence
AU - Cravedi, Jean-Pierre
AU - Fowler, Paul
AU - Franz, Roland
AU - Grob, Konrad
AU - Gürtler, Rainer
AU - Husøy, Trine
AU - Kärenlampi, Sirpa
AU - Mennes, Wim
AU - Milana, Maria Rosaria
AU - Penninks, André
AU - Smith, Andrew
AU - Tavares Poças, Maria de Fátima
AU - Tlustos, Christina
AU - Wölfle, Detlef
AU - Zorn, Holger
AU - Zugravu, Corina-Aurelia
AU - Chesson, Andrew
AU - Glandorf, Boet
AU - Herman, Lieve
AU - Jany, Klaus-Dieter
AU - Marcon, Francesca
AU - Želježic, Davor
AU - Aguilera-Gómez, Margarita
AU - Andryszkiewicz, Magdalena
AU - Divéki, Zoltán
AU - Kovalkovičová, Natália
AU - Engel, Karl-Heinz
PY - 2017/8
Y1 - 2017/8
N2 - The food enzyme considered in this opinion is a β-amylase (4-α-d-glucan maltohydrolase; EC 3.2.1.2), produced with genetically modified Bacillus licheniformis strain NZYM-JA by Novozymes A/S (Denmark). The β-amylase food enzyme is intended to be used in starch processing for the production of glucose syrups. Since the residual amounts of total organic solids (TOS) in glucose syrups after filtration and purification during starch processing were considered negligible, no dietary exposure was calculated. Toxicological tests made with the food enzyme under application indicated that there was no concern with respect to genotoxicity, mutagenicity or systemic toxicity. The allergenicity was evaluated by searching for similarity of the amino acid sequence to those of known allergens; no match was found. The Panel considers that there are no indications for allergic reactions. Based on the genetic modifications performed, the manufacturing process, the compositional and biochemical data provided, the findings in the toxicological studies and allergenicity assessment, the Panel concludes that this food enzyme does not give rise to safety concerns under the intended conditions of use.
AB - The food enzyme considered in this opinion is a β-amylase (4-α-d-glucan maltohydrolase; EC 3.2.1.2), produced with genetically modified Bacillus licheniformis strain NZYM-JA by Novozymes A/S (Denmark). The β-amylase food enzyme is intended to be used in starch processing for the production of glucose syrups. Since the residual amounts of total organic solids (TOS) in glucose syrups after filtration and purification during starch processing were considered negligible, no dietary exposure was calculated. Toxicological tests made with the food enzyme under application indicated that there was no concern with respect to genotoxicity, mutagenicity or systemic toxicity. The allergenicity was evaluated by searching for similarity of the amino acid sequence to those of known allergens; no match was found. The Panel considers that there are no indications for allergic reactions. Based on the genetic modifications performed, the manufacturing process, the compositional and biochemical data provided, the findings in the toxicological studies and allergenicity assessment, the Panel concludes that this food enzyme does not give rise to safety concerns under the intended conditions of use.
KW - food enzyme
KW - β-amylase
KW - 4-α-d-glucan maltohydrolase
KW - EC 3.2.1.2
KW - Bacillus licheniformis
KW - genetically modified microorganism
U2 - 10.2903/j.efsa.2017.4896
DO - 10.2903/j.efsa.2017.4896
M3 - Article
SN - 1831-4732
VL - 15
SP - e04896
JO - EFSA Journal
JF - EFSA Journal
PB - European Food Safety Authority (EFSA)
ER -